Follow the progress of Hemolens Diagnostics
This website contains information intended only for persons professionally dealing with medical devices (e.g. for persons performing medical professions, for persons dealing with the distribution of medical devices). Please confirm that you are a medical device professional to proceed.
Follow the progress of Hemolens Diagnostics
April 25, 2024
Poland, Warsaw April 23rd, 2023
Hemolens Diagnostics®, a trailblazer in the field of non-invasive diagnostic technology, has been bestowed with the prestigious Masters of Global Impact award in the latest edition of the competition. The accolade was presented by none other than Krzysztof Gawkowski, the Vice President of the Council of Ministers and Minister of Digitization, at a gala event organized by Masters & Robots.
The recognition underscores Hemolens Diagnostics’® relentless pursuit of innovation and its unwavering commitment to addressing critical healthcare challenges on a global scale. Renowned for its groundbreaking advancements in diagnostic solutions, Hemolens® has continually pushed the boundaries of technology to improve patient care and outcomes.
The Masters of Global Impact award, organized by Masters & Robots, serves as a platform to honor organizations and individuals who have demonstrated exceptional leadership and innovation in driving positive social and environmental impact through technology. Hemolens Diagnostics’® recognition in this category reflects its outstanding contributions towards advancing global health and well-being.
Accepting the award on behalf of Hemolens Diagnostics®, CEO Marek Wypych expressed gratitude for the recognition and reaffirmed the company’s commitment to leveraging technology for the betterment of humanity. He emphasized Hemolens’® dedication to developing cutting-edge solutions that will empower healthcare professionals and improve patient outcomes across the globe.
As Hemolens® continues to push the boundaries of non-invasive diagnostic technology, its receipt of the Masters of Global Impact award serves as a testament to its position as a pioneering force in the healthcare industry, driving meaningful change and transforming lives through innovation.
Intended Use:
Cardiolens FFR-CT Pro is a coronary physiologic simulation software for the clinical quantitative and qualitative analysis of previously acquired Coronary Computed Tomography Angiography (CCTA) and optionally with Continuous Non-invasive Blood Pressure (CNBP) data for assessment of patients with suspected Chronic Coronary Syndromes (CCS). It provides hemodynamic diagnostic factor FFR-CT (Fractional Flow Reserve with Computed Tomography), a mathematically derived quantity, computed from simulated pressure, velocity and blood flow information obtained from a 3D computer model generated from static coronary CT images and optionally from CNBP measurement. The factor FFR-CT at the output of Cardiolens FFR-CT Pro device is intended to support the functional evaluation of coronary artery disease. The Cardiolens FFR-CT Pro outputs are provided to support qualified clinicians to aid in the evaluation and assessment of coronary arteries. The results of Cardiolens FFR-CT Pro are intended to be used by qualified clinicians in conjunction with the patient’s clinical history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgment.